We also encountered preliminary evidence to suggest that the Ro+R-CHOP combination may be particularly beneficial to patients diagnosed with high-risk genetic subtypes of DLBCL, namely MCD and A53. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.